Last reviewed · How we verify
NCT05653492
Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease
Phase 2 trial testing Sulforaphane in Pediatric Kidney Disease in 12 participants. Participants enrolled and being followed up; not accepting new ones.
30 April 2025
Quick facts
| Lead sponsor | University of Rochester |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 15 May 2023 |
| Primary completion | 30 April 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Sulforaphane — full drug profile →
Conditions studied
- Pediatric Kidney Disease — all drugs for Pediatric Kidney Disease →
Sponsor
University of Rochester
Who can join
Adults 1 to 17, any sex, with Pediatric Kidney Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include preliminary exploration of changes in oxidative and inflammatory biomarkers in response to SFN supplementation in this population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05653492
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sulforaphane
Trials testing the same drug.
- NCT06594536 — Study of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperacti · NA · not yet recruiting
- NCT07047976 — Mechanism Study of Sulforaphane in ASD Improvement · NA · withdrawn
- NCT04848792 — Treatment Strategy to Enhance Nrf2 Signaling in Older Adults · NA · completed
- NCT04805957 — Validation Digital Bio-markers During Sulforaphane Treatment. · NA · enrolling by invitation
- NCT05408559 — Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES · Phase 1, PHASE2 · recruiting
Other recruiting trials for Pediatric Kidney Disease
Currently open trials in the same condition.
- NCT06430684 — Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease · EARLY_PHASE1 · recruiting
- NCT03719339 — VIRTUUS Children's Study · active not recruiting
Other University of Rochester trials
Trials by the same sponsor.
- NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
- NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
- NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
- NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
- NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05653492 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rochester
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05653492.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing